An investigation into price fixing in the generic drug sector has expanded to include at least 16 companies and 300 drugs, Washington Post reported Monday.
"This is most likely the largest cartel in the history of the [US]," remarked Connecticut Assistant Attorney General Joseph Nielsen, citing the number of drugs and "total number of companies involved, and individuals."
In one example, the price of the asthma drug albuterol, sold by Mylan and Sun Pharmaceutical, has surged by more than 3400 percent from $0.13 per tablet to more than $4.70 per tablet.
In another scheme, Heritage Pharmaceuticals and Dr. Reddy’s Laboratories agreed to divide the market and inflate the price for the cancer drug zoledronic acid after the latter drugmaker received FDA approval to launch a generic version of the drug in 2013.
Meanwhile, Heritage reached a similar agreement with Mylan over the antibiotic doxycycline in 2013.
"We have been investigating these allegations thoroughly and have found no evidence of price fixing on the part of Mylan or its employees," Mylan stated adding "Mylan has deep faith in the integrity of its president, Rajiv Malik, and stands behind him fully."
To read more NewsPoints articles, click here.